Saudi Arabia Artificial lungs Market Overview, 2031

The artificial lungs market in Saudi Arabia has steadily developed alongside broader advances in respiratory and organ-support technologies. Initially limited to a few specialized hospitals, artificial lungs delivered via extracorporeal membrane oxygenation (ECMO) systems or heart-lung machines have become more sophisticated, incorporating advanced sensors, monitoring, and data-driven controls to support critical respiratory or heart–lung failure. This evolution has expanded their use beyond acute, last-resort interventions to intensive care units, post-surgical care, and as bridges during transplants or recovery from severe lung diseases. Demand in Saudi Arabia is driven by a rising prevalence of chronic respiratory conditions, increasing critical-care needs, and substantial government investment in healthcare infrastructure. Regulatory oversight by the Saudi Food and Drug Authority (SFDA) ensures compliance with high-risk device classifications, import registration, unique device identification, international safety standards such as IEC 60601, and quality-management norms like ISO 13485. The nationwide ECMO program launched in 2021, offering a 24/7 consultation hotline and hospital support, exemplifies government efforts to increase access to these technologies. Demographic shifts, including an aging population and higher chronic respiratory disease rates, are expanding the customer base for long-term or intensive respiratory support. Both patients and healthcare institutions are increasingly adopting advanced hospital-grade systems over conventional ventilators, reflecting a preference for comprehensive respiratory care. Within the larger artificial organs and respiratory devices market, artificial lungs serve critical roles in cardiopulmonary surgery, transplant support, and long-term respiratory management. Saudi Arabia leads the Middle East and Africa in adopting such technologies, supported by strong public-private partnerships, growing clinical expertise, and expanding critical-care infrastructure.

According to the research report, "Saudi Arabia Artificial lungs Overview, 2031," published by Bonafide Research, the Saudi Arabia Artificial lungs is anticipated to grow at more than 12.5% CAGR from 2026 to 2031.In Saudi Arabia, large-scale local manufacturing of artificial-lung or ECMO/heart-lung devices is limited, with the market primarily served by international med-tech companies such as Medtronic, Getinge, Terumo, and LivaNova. Local distributors and medical-equipment suppliers handle import, distribution, regulatory registration, after-sales support, and supply of consumables and accessories. Saudi-based firms like Kafou Medical Co. and Attieh Medico distribute hospital devices including anesthesia, surgical, and respiratory-care equipment. Products in this segment include static ECMO or heart-lung machines, oxygenators, blood pumps, tubing sets, cannulae, heater-cooler units, and disposable oxygenation or circulation components. Procurement is mostly hospital-based, often through tenders or direct contracts with tertiary hospitals, transplant centers, and ICUs, due to the need for specialized infrastructure, trained personnel, and ongoing maintenance. Recent trends show growing adoption of portable and compact ECMO systems, enabling intra-hospital transport or ambulance-based use, creating opportunities for distributors offering hardware, consumables, training, and service. Barriers remain high, including the significant capital cost of machines and disposables and the need for certified staff such as perfusionists and ICU personnel, limiting broader adoption and keeping conventional ventilators and non-invasive respiratory support relevant in cost- or staff-constrained settings. Hospitals in Riyadh, Jeddah, and Dammam account for the majority of ECMO installations, reflecting the concentration of advanced cardiac and critical-care facilities in major urban centers. In addition, the ongoing expansion of ICU beds, increased government healthcare spending, and the rising prevalence of cardiac and respiratory conditions are gradually increasing the demand for ECMO and heart-lung devices in specialized hospitals across the Kingdom.

Artificial lung technologies have evolved significantly over the years to address the challenges of respiratory failure and complex cardiorespiratory conditions. Extracorporeal Membrane Oxygenation (ECMO), membrane oxygenators, and heart-lung machines represent the core, established technologies for artificial lung support. In ECMO, blood is circulated outside the body through a membrane oxygenator often a hollow fiber bundle where oxygen is added and carbon dioxide removed before returning to the patient. Over decades, improvements in membrane materials, such as polymethyl pentene, have enhanced gas-exchange efficiency while reducing risks like hemolysis and clotting. Modern ECMO machines are safer, easier to manage, and in some cases can be maintained by a single bedside nurse, providing support for days or even weeks, with applications spanning acute respiratory failure, pre- and post-surgical support, and bridging to lung transplantation. Recent research is moving beyond traditional hollow fiber oxygenators toward microfluidic artificial lungs and other emerging oxygenation technologies that better replicate the microvascular structure of natural lungs. Microfluidic devices use ultrathin, gas-permeable membranes and microchannel networks to reduce blood trauma and clotting, while biohybrid lungs with endothelialized surfaces improve hemocompatibility for longer-term support. Some innovations are exploring hybrid systems that combine ventricular assist devices (VADs) with oxygenation, supporting both heart and lung function in patients with combined failure. Other research-phase technologies include fully implantable or wearable lungs, pump-less lung assist devices, and cell-lined oxygenators aimed at reducing thrombosis and inflammatory responses. Compared with traditional ECMO and heart-lung machines, these emerging approaches offer improved gas exchange, lower flow resistance, and potentially smaller, portable, or implantable designs while extending support to patients with complex cardiorespiratory needs.

Hospitals and medical centers are the primary end-users of ECMO, artificial lungs, and heart-lung machines. Large tertiary and multi-specialty hospitals integrate these devices into ICUs to manage severe respiratory failure, post-surgical complications, or acute pulmonary distress, maintaining membrane oxygenators, disposable tubing sets, and ECMO circuits, supported by trained perfusionists and critical care staff. Cardiac surgery centers rely on heart-lung machines during open-heart surgeries, valve replacements, and congenital defect repairs, often deploying ECMO postoperatively for temporary cardiac or pulmonary insufficiency, with advanced monitoring systems enabling high-volume use of consumables, oxygenators, and pumps. Emergency care facilities adopt ECMO or portable artificial lung systems for rapid response to ARDS, trauma-induced lung failure, or severe COVID-19 complications, with portable units allowing pre-ICU stabilization and patient transport. Transplant centers use artificial lungs as a bridge-to-transplant strategy, stabilizing patients awaiting donor organs and requiring specialized perfusionist training for complex pre- and post-transplant care. Specialized ICUs managing severe respiratory or multi-organ failure increasingly implement artificial-lung systems for patients unable to maintain oxygenation through conventional ventilation, driven by rising chronic lung disease and respiratory infections. High-end ambulatory surgical centers are gradually adopting compact ECMO and portable oxygenation systems for surgeries requiring temporary cardiopulmonary support or rapid post-operative stabilization. Across all end-users, trends include wider adoption of portable ECMO devices, emphasis on training programs, service agreements, and reliable disposable supplies, integration with hybrid VAD-oxygenation systems in cardiac and transplant centers, and ongoing research into bioengineered or microfluidic lung assist devices.

In recent years, artificial lungs and ECMO technologies have become indispensable tools in modern respiratory and cardiac care, supporting patients across a wide range of critical conditions. Artificial lungs and ECMO (extracorporeal membrane oxygenation) systems are critical in various clinical settings, starting with acute care, where they manage patients experiencing sudden respiratory failure, severe pneumonia, or ARDS. These devices support oxygenation and carbon dioxide removal when conventional ventilation is insufficient, with hospitals and ICUs closely monitoring patients and using advanced sensors to optimize flow and oxygen delivery. In cardiac surgery, heart-lung machines are indispensable during procedures such as open-heart surgeries, valve replacements, and congenital heart defect repairs, while ECMO can provide postoperative support for temporary cardiac or pulmonary insufficiency, integrated seamlessly into perfusion workflows to regulate oxygenation, perfusion, and temperature. In emergency resuscitation, portable ECMO and artificial-lung devices enable rapid intervention in trauma cases, severe cardiac arrest, or COVID-19-induced respiratory failure, emphasizing mobility and speed before ICU transfer. For patients awaiting lung or heart-lung transplants, artificial lungs serve as a bridge-to-transplant therapy, maintaining oxygenation and preventing multi-organ deterioration, often combined with other support technologies. During lung transplantation, ECMO or artificial-lung devices provide intraoperative and postoperative support, ensuring adequate oxygenation while the donor organ begins functioning and may remain temporarily active post-surgery to reduce primary graft dysfunction. While traditionally used for short-term support, emerging bioengineered and microfluidic lungs are being explored for chronic respiratory support in patients with end-stage lung disease, potentially offering alternatives to long-term mechanical ventilation or transplantation. Portable ECMO systems, hybrid cardiac-oxygenation devices, and ongoing research in bioengineered lungs are gradually shaping these applications across acute, surgical, emergency, and chronic care scenarios.



Considered in this report
• Historic year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Saudi Arabia Artificial lungs Market with its value and forecast along with its segments
• Artificial lungs Market analysis
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Technology Type
• Extracorporeal Membrane Oxygenation (ECMO)
• Artificial Lung Devices
• Heart-Lung Machines
• Bioengineered Lung Tissues
• Membrane Oxygenators
• Ventricular Assist Devices with Oxygenation

By End-User
• Hospitals and Medical Centers
• Cardiac Surgery Centers
• Emergency Care Facilities
• Transplant Centers
• Specialized Intensive Care Units
• Ambulatory Surgical Centers

By Application
• Acute Care Applications
• Cardiac Surgery Support
• Emergency Resuscitation
• Bridge-to-Transplant Therapy
• Lung Transplantation Support
• Chronic Respiratory Support